Leukemic presentation of ALK-positive anaplastic large cell lymphoma with a novel partner, poly(A) binding protein cytoplasmic 1 (PABPC1), responding to single-agent crizotinib

Anaplastic large cell lymphoma (ALCL) is a subtype of non-Hodgkin lymphoma (NHL) characterized by T or null phenotype pleomorphic cells that express CD30. Systemic ALCL is sub-classified into two distinct entities, ALK-positive (ALK+ ALCL) and ALK-negative (ALK− ALCL), according to whether it